These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 20850487)
21. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. Sin JI; Kim JJ; Arnold RL; Shroff KE; McCallus D; Pachuk C; McElhiney SP; Wolf MW; Pompa-de Bruin SJ; Higgins TJ; Ciccarelli RB; Weiner DB J Immunol; 1999 Mar; 162(5):2912-21. PubMed ID: 10072541 [TBL] [Abstract][Full Text] [Related]
22. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice. Tengvall S; Josefsson A; Holmgren J; Harandi AM J Reprod Immunol; 2005 Dec; 68(1-2):53-69. PubMed ID: 16229896 [TBL] [Abstract][Full Text] [Related]
23. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection. Da Costa XJ; Morrison LA; Knipe DM Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa. Milligan GN; Dudley-McClain KL; Chu CF; Young CG Virology; 2004 Jan; 318(2):507-15. PubMed ID: 14972519 [TBL] [Abstract][Full Text] [Related]
25. Influenza A vaccines using linear expression cassettes delivered via electroporation afford full protection against challenge in a mouse model. Shen X; Söderholm J; Lin F; Kobinger G; Bello A; Gregg DA; Broderick KE; Sardesai NY Vaccine; 2012 Nov; 30(48):6946-54. PubMed ID: 22406460 [TBL] [Abstract][Full Text] [Related]
28. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. Meseda CA; Elkins KL; Merchlinsky MJ; Weir JP J Infect Dis; 2002 Oct; 186(8):1065-73. PubMed ID: 12355355 [TBL] [Abstract][Full Text] [Related]
29. Dry coating of immunotherapeutics to densely packed and short microprojection arrays. Park K J Control Release; 2009 Nov; 139(3):171. PubMed ID: 19735682 [No Abstract] [Full Text] [Related]
30. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. Macmillan L; Ifere GO; He Q; Igietseme JU; Kellar KL; Okenu DM; Eko FO FEMS Immunol Med Microbiol; 2007 Feb; 49(1):46-55. PubMed ID: 17094789 [TBL] [Abstract][Full Text] [Related]
31. A low-invasive and effective transcutaneous immunization system using a novel dissolving microneedle array for soluble and particulate antigens. Matsuo K; Yokota Y; Zhai Y; Quan YS; Kamiyama F; Mukai Y; Okada N; Nakagawa S J Control Release; 2012 Jul; 161(1):10-7. PubMed ID: 22306332 [TBL] [Abstract][Full Text] [Related]
32. Microprojection arrays to immunise at mucosal surfaces. McNeilly CL; Crichton ML; Primiero CA; Frazer IH; Roberts MS; Kendall MA J Control Release; 2014 Dec; 196():252-60. PubMed ID: 25285611 [TBL] [Abstract][Full Text] [Related]
33. Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. Fernando GJ; Chen X; Primiero CA; Yukiko SR; Fairmaid EJ; Corbett HJ; Frazer IH; Brown LE; Kendall MA J Control Release; 2012 Apr; 159(2):215-21. PubMed ID: 22306334 [TBL] [Abstract][Full Text] [Related]
34. Skin targeted DNA vaccine delivery using electroporation in rabbits. I: efficacy. Medi BM; Hoselton S; Marepalli RB; Singh J Int J Pharm; 2005 Apr; 294(1-2):53-63. PubMed ID: 15814230 [TBL] [Abstract][Full Text] [Related]
35. [Novel vaccines against M. tuberculosis]. Okada M Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920 [TBL] [Abstract][Full Text] [Related]
36. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Mo A; Musselli C; Chen H; Pappas J; Leclair K; Liu A; Chicz RM; Truneh A; Monks S; Levey DL; Srivastava PK Vaccine; 2011 Nov; 29(47):8530-41. PubMed ID: 21767588 [TBL] [Abstract][Full Text] [Related]
37. Maternal immunization with a herpes simplex virus type 2 replication-defective virus reduces visceral dissemination but not lethal encephalitis in newborn mice after oral challenge. Evans IA; Jones CA J Infect Dis; 2002 Jun; 185(11):1550-60. PubMed ID: 12023760 [TBL] [Abstract][Full Text] [Related]
38. Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Matriano JA; Cormier M; Johnson J; Young WA; Buttery M; Nyam K; Daddona PE Pharm Res; 2002 Jan; 19(1):63-70. PubMed ID: 11837701 [TBL] [Abstract][Full Text] [Related]
39. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. Fernando GJ; Chen X; Prow TW; Crichton ML; Fairmaid EJ; Roberts MS; Frazer IH; Brown LE; Kendall MA PLoS One; 2010 Apr; 5(4):e10266. PubMed ID: 20422002 [TBL] [Abstract][Full Text] [Related]
40. A microarray MEMS device for biolistic delivery of vaccine and drug powders. Pirmoradi FN; Pattekar AV; Linn F; Recht MI; Volkel AR; Wang Q; Anderson GB; Veiseh M; Kjono S; Peeters E; Uhland SA; Chow EM Hum Vaccin Immunother; 2015; 11(8):1936-44. PubMed ID: 26090875 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]